Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Lancet HIV. 2015 Apr 1;2(4):e151–e158. doi: 10.1016/S2352-3018(15)00021-1

Table 2. Factors associated with time to switch following viral load rebound using competing risk model.

Univariable
 Multivariable
n SHR 95% CI P SHR 95% CI P
Gender (female v male) 170 1·02 0·67 - 1·54 0·93
Age at ART initiation (per 5 years higher) 170 1·05 0·85 - 1·28 0·67
CD4% at ART initiation (per 5% higher) 145 0·85 0·75 - 0·97 0·02
Age at VL rebound (per 5 years higher) 170 1·09 0·88 - 1·34 0·44 1·26 0·96 - 1·65 0·10
CD4% at VL rebound (per 5% higher) 160 0·90 0·80 - 1·00 0·04 0·89 0·78 - 1·01 0·07
Viral load at VL rebound (per log10 copies/ml higher) 170 1·72 1·29 - 2·27 0·0002 1·88 1·39 - 2·55 <0·0001
Time on ART until VL rebound (per 6 months higher) 170 1·02 0·96 - 1·09 0·44
Regimen at ART initiation 170 0·01 0·001
 EFV+2NRTI 1 1
 NVP+2NRTI 0·88 0·54 - 1·44 1·21 0·69 - 2·13
 Boosted PI+NRTI 0·18 0·07 - 0·48 0·13 0·05 - 0·38
 NNRTI+3NRTI 0·90 0·46 - 1·74 1·78 0·81 - 3·92
 ABC+2NRTI 0·76 0·40 - 1·43 1·45 0·73 - 2·91
Calendar year at VL rebound 170 0·97 0·02
 1996 - 2003 1 1
 2004 - 2007 1·06 0·65 - 1·74 1·28 0·71 - 2·30
 2008 - 2011 1·04 0·64 - 1·69 2·38 1·23 - 4·60

ABC, Abacavir; ART, Antiretroviral therapy; CI, Confidence interval; EFV, Efavirenz; NNRTI, Nonnucleoside reverse transcriptase inhibitor; NRTI, Nucleoside reverse transcriptase inhibitor; NVP, Nevirapine; PI, Protease inhibitor; SHR, Sub hazard ratio; VL, Viral load.